Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

QN-302: Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.

Study summary

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer).

Main questions:

* What does the study drug do to human body (Pharmacodynamics \[='PD'\])
* What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety

Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.

Eligibility

Primary outcome measure(s)

• Determine MTD — 18 months
  maximum tolerated dose identified from dose escalation cohorts
• Establish RP2D — 24 months
  recommended Phase 2 dose identified from dose escalation cohorts

Trial sites (4)

Other trials for the same condition